PS-116-Use of cyclooxygenase inhibitor and the risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nested case-control study using a nationwide population-based data

2019 ◽  
Vol 70 (1) ◽  
pp. e73
Author(s):  
Sohn Won ◽  
Kyoung Sun Cho ◽  
Jung Hee Kim ◽  
Ju-Yeon Cho ◽  
Yong Han Paik
2011 ◽  
Vol 131 (5) ◽  
pp. 1197-1202 ◽  
Author(s):  
Qiang Li ◽  
Wen-Wen Li ◽  
Xia Yang ◽  
Wen-Bo Fan ◽  
Jin-Hong Yu ◽  
...  

PLoS ONE ◽  
2012 ◽  
Vol 7 (1) ◽  
pp. e29928 ◽  
Author(s):  
Qiang Li ◽  
Cui-Hua Yu ◽  
Jin-Hong Yu ◽  
Li Liu ◽  
Shuang-Shuang Xie ◽  
...  

2008 ◽  
Vol 89 (11) ◽  
pp. 2882-2890 ◽  
Author(s):  
Zhong-Liao Fang ◽  
Caroline A. Sabin ◽  
Bai-Qing Dong ◽  
Shao-Chao Wei ◽  
Qin-Yan Chen ◽  
...  

A matched nested case–control study of 33 paired cases and controls was conducted, based on a study cohort in Long An county, Guangxi, China, to determine whether infection with hepatitis B virus (HBV) with pre-S deletions is independently associated with the development of hepatocellular carcinoma (HCC), without the confounding effects of basal core promoter (BCP) double mutations. The prevalence of pre-S deletions was significantly higher in HCC (45.5 %, 15 of 33) than the controls (18.2 %, 6 of 33) (P<0.01), under the control of the influence of BCP double mutations. Most of the pre-S deletions occurred in, or involved, the 5′ half of the pre-S2 region and the difference between HCC (93.3 %, 14 of 15) and controls (66.7 %, four of six) was significant for this region (P=0.015). There was no significant difference in pre-S deletions between the BCP mutant group and BCP wild-type group (P>0.05), nor was the prevalence of pre-S deletions significantly different between genotypes B and C (P>0.1). These results suggest that pre-S deletions constitute an independent risk factor for HCC and their emergence and effect are independent of BCP mutations. The 5′ terminus of pre-S2 is the favoured site for the deletion mutations, especially in HCC cases. Further prospective studies are required to confirm the role of these mutations in the development of HCC.


2009 ◽  
Vol 16 (6) ◽  
pp. 430-436 ◽  
Author(s):  
A. Mavrogiannaki ◽  
B. Karamanos ◽  
E. K. Manesis ◽  
G. V. Papatheodoridis ◽  
J. Koskinas ◽  
...  

2020 ◽  
Vol 81 (2-3) ◽  
pp. 79-84
Author(s):  
Jonas Michel Wolf ◽  
Vagner Reinaldo Zingalli Bueno Pereira ◽  
Patrícia Andréia Zanetti Ballardin Roncato ◽  
André Castagna Wortmann ◽  
Glaucia Zuleide Stumm ◽  
...  

2016 ◽  
Vol 43 (11) ◽  
pp. 1197-1207 ◽  
Author(s):  
P. P. Gounder ◽  
L. R. Bulkow ◽  
M. Snowball ◽  
S. Negus ◽  
P. R. Spradling ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document